Ignite Creation Date:
2024-05-06 @ 8:20 PM
Last Modification Date:
2024-10-26 @ 3:25 PM
Study NCT ID:
NCT06346509
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-04
First Post:
2024-03-21
Brief Title:
Randomized Double-Blind Placebo-Controlled Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants
Sponsor:
Portal Therapeutics Inc
Organization:
Portal Therapeutics Inc
Study Overview
Official Title:
A Phase 1 First-in-Human Randomized Double-Blind Placebo-Controlled Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A First-in-Human 2-part randomized double-blind placebo-controlled single ascending dose multiple ascending dose and food effect investigation of the administration of PORT-77 in healthy adult participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None